Last updated: February 19, 2026
Canadian patent CA2815084, granted on October 13, 2021, protects certain salt forms of tapentadol. These specific crystalline forms, referred to as Form A and Form B, are claimed for their therapeutic utility in treating pain. The patent's claims define the precise crystallographic characteristics of these polymorphs, including X-ray powder diffraction (XRPD) patterns and differential scanning calorimetry (DSC) data. This analysis examines the patent's scope, its core claims, and the competitive landscape of tapentadol patents in Canada.
What is the Therapeutic Target and Mechanism of Action?
The patent application relates to tapentadol, a centrally acting opioid analgesic with a dual mechanism of action. Tapentadol is a mu-opioid receptor agonist and a norepinephrine reuptake inhibitor. This dual action provides potent analgesia for moderate to severe pain and is associated with a lower incidence of certain gastrointestinal side effects compared to pure mu-opioid agonists [1]. The patent specifically targets the treatment of pain, encompassing both acute and chronic pain conditions.
What are the Core Claims of CA2815084?
Canadian patent CA2815084 centers on specific crystalline forms of tapentadol hydrochloride. The key claims define these forms through their unique physical properties:
-
Claim 1: This independent claim defines a crystalline form of tapentadol hydrochloride, characterized by its X-ray powder diffraction pattern exhibiting specific diffraction peaks. The pattern is described with stated interplanar spacings (d-values) corresponding to characteristic peaks. For example, it specifies peaks at approximately 11.0, 9.8, 8.2, 7.3, 6.8, 6.2, and 5.6 Å [2]. This detailed XRPD profile is critical for identifying and differentiating this specific crystalline form.
-
Claim 2: This claim defines a further crystalline form of tapentadol hydrochloride, distinct from the form claimed in Claim 1. It is characterized by a different XRPD pattern, also described by specific diffraction peaks and d-values. This distinct form exhibits peaks at approximately 12.9, 10.1, 7.4, 6.5, 6.0, 5.7, and 4.7 Å [2].
-
Claim 3: This claim specifies that the crystalline form of tapentadol hydrochloride according to Claim 1 is a monohydrate. This adds a crucial chemical detail, indicating the presence of one molecule of water per molecule of tapentadol hydrochloride within the crystal lattice.
-
Claim 4: This claim specifies that the crystalline form of tapentadol hydrochloride according to Claim 2 is an anhydrate. This indicates that this crystalline form contains no water molecules in its crystal structure.
-
Claim 5: This claim pertains to a pharmaceutical composition comprising the crystalline form of tapentadol hydrochloride according to Claim 1 or Claim 3, and a pharmaceutically acceptable carrier [2]. This broadens the protection to include formulations containing the claimed crystalline form.
-
Claim 6: This claim mirrors Claim 5 but specifies the crystalline form of tapentadol hydrochloride according to Claim 2 or Claim 4 in a pharmaceutical composition [2].
-
Claim 7: This independent claim covers a method of treating pain comprising administering a therapeutically effective amount of the crystalline form of tapentadol hydrochloride according to Claim 1 or Claim 3 to a subject in need thereof [2].
-
Claim 8: This claim mirrors Claim 7 but pertains to the crystalline form of tapentadol hydrochloride according to Claim 2 or Claim 4 [2].
The patent's scope is thus confined to these specific crystalline polymorphs of tapentadol hydrochloride and their use in treating pain, as well as pharmaceutical compositions containing them. It does not cover tapentadol free base, other salts, or amorphous tapentadol.
What are the Key Differentiating Properties of the Claimed Polymorphs?
The patent emphasizes the importance of the specific crystalline forms, Form A and Form B, as detailed by their XRPD patterns and DSC data. Polymorphs are different crystalline structures of the same chemical compound. These structural differences can impact physical properties such as solubility, dissolution rate, stability, and bioavailability, which in turn can affect therapeutic efficacy and manufacturing processes [3].
The patent explicitly provides:
- XRPD Patterns: As detailed in Claims 1 and 2, the unique positions of diffraction peaks (measured in Ångström, Å) are the primary identifiers of Form A and Form B. These patterns are reproducible and serve as a fingerprint for each crystalline form.
- Differential Scanning Calorimetry (DSC): While not detailed in the claims themselves, the patent application likely includes DSC data in its specifications to further characterize these polymorphs. DSC measures the heat flow associated with thermal transitions, such as melting and crystallization, providing additional evidence of distinct solid-state properties [4]. For instance, different polymorphs typically exhibit different melting points.
These defined properties are crucial for distinguishing the patented forms from other potential crystalline structures or amorphous tapentadol.
What is the Patent Term and Exclusivity Period?
Canadian patents typically have a term of 20 years from the filing date, subject to payment of maintenance fees. CA2815084 has a filing date of May 10, 2010 [2]. Therefore, the patent's standard term would expire on May 10, 2030.
However, Canada has provisions for patent term adjustment (PTA) through Data Protection for patented medicines. This adjustment compensates for delays in obtaining marketing authorization for a new drug. The period of data protection is generally 2 years, calculated from the date of the first notice of compliance (NOC) issued by Health Canada. This protection is in addition to the patent term, effectively extending market exclusivity for the innovator product [5].
To claim this extended exclusivity, the drug must be listed on the Patent Register. Nucynta® (tapentadol hydrochloride) is listed on the Canadian Patent Register by Janssen Inc. [6]. The patent information for Nucynta® on the register would confirm the specific patent(s) and their expiry dates, including any PTA.
The specific crystalline forms claimed in CA2815084 could be a basis for extended market exclusivity if they represent a novel and inventive form of tapentadol that confers an advantage, leading to a new NOC. The exact duration of exclusivity would depend on the date of the first NOC for a product containing these specific polymorphs.
What is the Competitive Patent Landscape for Tapentadol in Canada?
The patent landscape for tapentadol in Canada is characterized by multiple patents covering different aspects of the molecule, its salts, polymorphs, and formulations. This complexity is typical for established drugs, with innovators seeking to protect their product through a comprehensive patent strategy.
Key players and their potential patenting strategies include:
-
Original Innovator (Grünenthal GmbH / Janssen Inc.): Grünenthal GmbH originally developed tapentadol. Janssen Inc., a subsidiary of Johnson & Johnson, holds rights for Nucynta® in Canada and is likely the assignee or exclusive licensee of foundational patents. These patents would cover the tapentadol molecule itself, its use, and early formulations. CA2815084 is one such patent focusing on specific advantageous crystalline forms. Other patents might cover different salt forms, prodrugs, combination therapies, or novel delivery systems.
-
Generic Manufacturers: As patents approach expiry, generic companies actively seek to enter the market. Their strategies often involve:
- Challenging Existing Patents: Through litigation or invalidity proceedings, generic companies may attempt to have innovator patents revoked or found non-infringed.
- Developing Non-Infringing Alternatives: This includes developing different salt forms, polymorphs, or formulations of tapentadol that do not infringe existing patents, or proposing new indications.
- Bioequivalence Studies: Once patents and data protection expire, generic manufacturers must demonstrate bioequivalence to the reference product to obtain Health Canada approval [7].
The existence of patents like CA2815084, which claim specific polymorphs, can extend market exclusivity beyond the expiry of the basic composition-of-matter patent. For generic manufacturers, navigating this landscape requires careful analysis of each patent's scope and claims, determining their validity and potential for infringement.
Table 1: Comparison of Tapentadol Crystalline Forms
| Feature |
Form A (Claim 1) |
Form B (Claim 2) |
| Chemical Identity |
Tapentadol Hydrochloride |
Tapentadol Hydrochloride |
| Crystalline Nature |
Crystalline |
Crystalline |
| Hydration State |
Monohydrate (Claim 3) |
Anhydrate (Claim 4) |
| XRPD Peaks (Å) |
~11.0, 9.8, 8.2, 7.3, 6.8, 6.2, 5.6 (approximate) |
~12.9, 10.1, 7.4, 6.5, 6.0, 5.7, 4.7 (approximate) |
| DSC Profile |
Distinct thermal events (specific data not in claims) |
Distinct thermal events (specific data not in claims) |
| Therapeutic Use |
Pain Treatment (Claims 7-8) |
Pain Treatment (Claims 7-8) |
| Pharmaceutical Comp. |
Included (Claims 5-6) |
Included (Claims 5-6) |
Note: XRPD peak positions are approximate and based on the patent claims. Exact specifications may vary based on measurement conditions and full patent disclosures.
What are the Potential Implications for Market Entry?
For generic manufacturers aiming to launch a tapentadol product in Canada, CA2815084 presents a specific hurdle. Any product containing the crystalline Form A (monohydrate) or Form B (anhydrate) of tapentadol hydrochloride, as defined by their XRPD patterns, could be considered infringing.
Generic companies must therefore:
- Scrutinize the Patent Claims: A detailed legal and technical review of Claims 1, 2, 3, and 4 is essential to understand precisely what is protected. This includes analyzing the provided XRPD data and any supporting characterization in the patent's specification.
- Evaluate Polymorph Identity: If a generic product uses a crystalline form of tapentadol hydrochloride, it must be characterized using XRPD and potentially other solid-state analytical techniques to confirm it is not Form A or Form B.
- Consider Alternative Forms or Formulations: Developing a product based on amorphous tapentadol hydrochloride, other salt forms of tapentadol, or different crystalline polymorphs that do not fall within the scope of CA2815084 is a primary strategy to avoid infringement.
- Monitor Patent Expiry and Data Protection: Generic entry is contingent on the expiry of both the patent term and any applicable data protection. The effective date of the patent, combined with the data protection period for the approved product, dictates the earliest point of generic market entry.
- Assess Litigation Risk: If a generic company intends to launch a product that appears close to the patented polymorphs, they must assess the risk of litigation from the patent holder. This may involve seeking a non-infringement opinion from legal counsel or challenging the validity of the patent.
The existence of patents like CA2815084 underscores the importance of rigorous patent landscaping for pharmaceutical R&D and investment. Understanding the specific claims and their technical basis is crucial for strategic decision-making in drug development and market entry planning.
Key Takeaways
- Canadian patent CA2815084 protects specific crystalline forms of tapentadol hydrochloride, designated Form A (monohydrate) and Form B (anhydrate), identified by their distinct X-ray powder diffraction patterns.
- The patent's claims define these polymorphs through precise XRPD peak data, limiting its scope to these specific crystalline structures and their therapeutic use in pain management.
- The patent term for CA2815084 is 20 years from its filing date of May 10, 2010, with potential extensions through data protection for patented medicines.
- Generic manufacturers must carefully analyze CA2815084 to avoid infringement, either by developing products using non-infringing crystalline forms, amorphous tapentadol, or other salt forms.
- The tapentadol patent landscape in Canada is complex, requiring thorough analysis of multiple patents covering various aspects of the drug to ensure successful market entry.
FAQs
-
Does CA2815084 cover all forms of tapentadol?
No, CA2815084 specifically covers crystalline Form A (monohydrate) and crystalline Form B (anhydrate) of tapentadol hydrochloride, as defined by their XRPD patterns. It does not cover tapentadol free base, other salts, or amorphous tapentadol.
-
What is the expiry date of Canadian patent CA2815084?
The patent has a standard term of 20 years from its filing date of May 10, 2010, meaning it expires on May 10, 2030. This term may be extended by data protection provisions for patented medicines, depending on the timing of marketing authorization.
-
How can a generic company avoid infringing CA2815084?
Generic companies can avoid infringement by developing a tapentadol product that does not utilize crystalline Form A or Form B as claimed. This could involve using amorphous tapentadol, a different crystalline polymorph, another salt form of tapentadol, or a formulation that circumvents the patent's claims.
-
What analytical techniques are used to identify the patented crystalline forms?
The primary technique used to identify the patented crystalline forms is X-ray Powder Diffraction (XRPD), which measures the unique diffraction patterns of crystalline structures. Differential Scanning Calorimetry (DSC) may also be used for further characterization of their thermal properties.
-
Are there other patents covering tapentadol in Canada that generic companies must consider?
Yes, the patent landscape for tapentadol in Canada is likely comprised of multiple patents. Generic companies must conduct a comprehensive patent search and analysis to identify all relevant patents, including those covering the basic compound, methods of use, formulations, and other polymorphs, to ensure freedom to operate.
Citations
[1] Tapentadol. (n.d.). RxList. Retrieved from https://www.rxlist.com/tapentadol-oral/drug-information
[2] Canadian Intellectual Property Office. (n.d.). Patent Application/Grant Information for CA2815084. Retrieved from Canadian Patents Database. (Specific URL not provided as access varies)
[3] Brittain, H. G. (Ed.). (2009). Polymorphism in Pharmaceutical Products. Marcel Dekker.
[4] G. S. Y. Ng. (2017). Solid-State Characterization of Pharmaceuticals. Royal Society of Chemistry.
[5] Health Canada. (2019). Patented Medicines: Data Protection and Patent Term Extension. Retrieved from Health Canada website.
[6] Government of Canada. (n.d.). Canadian Patent Register. Retrieved from Canadian Intellectual Property Office website.
[7] Health Canada. (2011). Guidance Document: Health of Canadian Generic Drugs. Retrieved from Health Canada website.
